

## HR 6731

### Securing America's Pharmaceutical Supply Chain Act

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Government Operations and Politics

**Introduced:** May 5, 2020

**Current Status:** Referred to the Committee on Oversight and Reform, and in addition to the Committee on Ways and Means

**Latest Action:** Referred to the Committee on Oversight and Reform, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (May 5, 2020)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/6731>

### Sponsor

**Name:** Rep. Stauber, Pete [R-MN-8]

**Party:** Republican • **State:** MN • **Chamber:** House

### Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Garamendi, John [D-CA-3]	D · CA		May 5, 2020
Rep. Gibbs, Bob [R-OH-7]	R · OH		May 19, 2020
Rep. Hagedorn, Jim [R-MN-1]	R · MN		May 19, 2020

### Committee Activity

Committee	Chamber	Activity	Date
Ways and Means Committee	House	Referred To	May 5, 2020

### Subjects & Policy Tags

#### Policy Area:

Government Operations and Politics

### Related Bills

*No related bills are listed.*

## **Securing America's Pharmaceutical Supply Chain Act**

This bill allows an executive agency to purchase a drug approved or licensed by the Food and Drug Administration only if the drug is over 50% sourced, manufactured, and assembled in the United States.

This requirement may be waived (1) if the drug is not available in sufficient quantity or quality as over 50% sourced, manufactured, and assembled in the United States; or (2) during an emergency.

The U.S. Trade Representative (USTR) shall modify U.S. product coverage under all free trade agreements and the World Trade Organization Agreement on Government Procurement to exclude coverage of essential medicines and medical countermeasures. Subsequent to such modifications, the USTR shall make any necessary corresponding modifications of existing waivers and notify the Office of Management and Budget.

## **Actions Timeline**

---

- **May 5, 2020:** Introduced in House
- **May 5, 2020:** Referred to the Committee on Oversight and Reform, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.